Connect with us

Health and Wellness

Meet the scientist conducting inclusive genetic research to transform healthcare in the Caribbean – Essence

Published

on

Photo source: CariGenetics

In a world where scientific progress often overlooks diversity, Dr. Carika Weldon stands out as a pioneer determined to revolutionize genetic research in the Caribbean. As the founder and CEO of the company CariGenetics— the first-ever women-founded genomics company based in the Caribbean — Dr. Weldon has spearheaded a movement to be sure that the advantages of precision medicine reach Caribbean communities and the diaspora. Its mission is to fill the gap in health care by tailoring advances to the unique genetic makeup of individuals of Caribbean descent. “The genetic diversity of the Caribbean is a treasure trove of information,” Dr. Weldon explained.

“Our goal at Carigenetics is to understand how our unique genetic makeup influences health outcomes and to use this knowledge to improve the well-being of Caribbean communities.” Founded in 2022, the Bermuda-based company specializes in genomic research to address common health issues in the Caribbean, including sickle cell, breast and prostate cancer. Weldon’s goal is to harness the power of precision medicine, which emphasizes tailoring health care to individual patients based on their unique genetic profiles, lifestyle and other aspects. This approach contrasts with the traditional, one-size-matches-all model, which goals to provide more targeted and effective therapies.

Dr. Weldon explains: “Precision medicine focuses on understanding an individual’s specific needs, which allows us to save time, optimize resources and solve problems faster. This not only leads to better patient outcomes, but also translates into savings for the healthcare system.” One of the most groundbreaking CariGenetic initiatives, the so-called A genome-wide pilot study of breast cancer in the Caribbean, is the first of its kind in the Caribbean. The study focused on understanding the genetic aspects contributing to higher cancer mortality rates in the region. It could pave the way for targeted, personalized therapies that would save countless lives.

Meet the scientist leading inclusive genetic research to transform healthcare in the Caribbean
Photo source: CariGenetics

This landmark study successfully recruited 102 participants, performed whole-genome sequencing locally, analyzed all 102 samples and started to discover latest genetic trends in breast cancer, marking 4 major milestones for the broader Caribbean community. Dr. Weldon, a Bermuda native, said she founded CariGenetics with the mission of empowering local scientists, reducing dependence on outside labs and constructing trust in the community for genetic testing. “The first problem, therefore, is that all the medicines currently on the market have been designed based on European genetic data covering only 15% of the world’s population. This means that 85% of the world, including us in the Caribbean, has no access to medicines,” she added.

The second point she explained is the history of exploitation and misuse of Black people in the name of science. For example, in the Tuskegee Experiment, which began in 1932, black men were secretly denied treatment for syphilis in order to monitor the progression of the disease. They “died, went blind, went mad, or experienced other serious health problems” due to the untreated disease. Similarly, in 1951, Henrietta Lacks’ cells were collected without her consent, which contributed to quite a few breakthroughs in medicine, including methods of treating cancer. However, her contributions weren’t appreciated during her lifetime.

These abuses have deepened long-standing deep mistrust between Black communities and the medical community, underscoring the urgent need for ethical reforms and inclusive research practices. “A history of abuse, like that of Henrietta Lacks and Tuskegee, has led to a lack of trust. If we had more black scientists and doctors, we could prevent such injustices,” Dr. Weldon said.

CariGenetics goals to increase the representation of individuals of African descent in genetic research by specializing in the wealthy genetic diversity of the Black Caribbean population. The organization also strives to empower local Black scientists and community members to actively participate in this work. Addressing the historical distrust resulting from the unethical treatment of Black communities in science, CariGenetics is working to change this narrative and rebuild trust through inclusive and ethical research practices.

This focus began with Dr. Weldon’s journey from emerging neuroscientist to CEO of CariGenetics. Dr. Weldon stated that from an early age she was fascinated by the intricacies of the human brain. She initially dreamed of becoming a neuroscientist, but her passion ultimately led her in a special direction. Dr. Weldon’s path took a decisive turn when she pursued a level in medical biochemistry in the UK, where she faced setbacks, including rejection from Oxford University. But her determination never wavered. She obtained her Ph.D. in Biochemistry, fueled by a deep curiosity about the “why” behind medical testing and genetic mechanisms, laying the foundation for her future work.

The turning point got here when Dr. Weldon learned of Iceland’s pioneering efforts in population genetics. Iceland’s success in sequencing the genetic material of its population inspired it to ask: “Why cannot we do something like this in Bermuda and the Caribbean? “We are genetically diverse and can provide unique insights,” shared Dr. Weldon with ESSENCE. This spark of inspiration later guided her scientific work and fueled her vision for CariGenetics.

This spark of inspiration later guided her work as a researcher at Oxford, where a groundbreaking study on African genetic material was published in 2019 found that individuals of African descent had 10% more genetic variability than the standard human reference genome, which was mainly Eurocentric. This highlighted the urgent need for more inclusive genetic testing.

Meet the scientist leading inclusive genetic research to transform healthcare in the Caribbean
Photo source: CariGenetics

Dr. Weldon’s commitment to the Caribbean region deepened during the COVID-19 pandemic when she returned to Bermuda to lead research efforts in the country as a scientific advisor to the Prime Minister and Laboratory Director of the Government COVID-19 Laboratory.

Her experience highlighted glaring gaps in the scientific infrastructure in the Caribbean, further fueling her desire to bring cutting-edge genomic research home. “With the pandemic, I noticed that we’d like more scientists and genetic research in the Caribbean. We were to this point behind that we had to send samples to one lab in Trinidad for the entire region. I wanted to create something sustainable, so I founded CariGenetics to give attention to the genetic makeup of the Caribbean,” he says

One of CariGenetics’ most progressive approaches involves the use of bio-NFTs (non-fungible tokens) to provide participants with ownership of their genetic data. This cutting-edge technology gives individuals control over their information and the ability to monetize it.

Dr. Weldon is prepared to make a difference through her work at CariGenetics. Her immediate goal is to expand research beyond the initial breast cancer study to include prostate cancer and expand that research to the Caribbean. By identifying latest genetic markers related to breast cancer and other cancers common in Caribbean populations, Dr. Weldon goals to facilitate earlier and more accurate diagnosis.

Her vision is to use these discoveries to tailor medical therapies specifically for Caribbean communities. This approach reflects successful models akin to a recent study in England that identified a novel genetic mutation in the local population, leading to the development of targeted screening protocols. Dr. Weldon wants to replicate this model in the Caribbean by improving preventive care and treatment. The initiative also goals to expand its reach, with plans to establish partnerships and conduct research in Trinidad and Tobago, Jamaica and Saint Lucia, in addition to other Caribbean countries.

The goal of this expansion is to construct a sturdy network of clinicians and researchers dedicated to improving health care outcomes for the Caribbean population. “Genetic testing may also help us move away from a one-size-matches-all approach to medicine, but we also need to engage and construct trust in our communities. That’s what CariGenetics is for,” Dr. Weldon said.

This article was originally published on : www.essence.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending